For example, tumours previously deemed HER-2 negative which express that these variants above a specified threshold may in fact benefit from therapies targeting the HER-2 spliced variant thereby improving stratification of patients to “individualized” treatments. The gene discussed is ERBB2; the disease is neoplasm.